Exchange: NASDAQ·Updated 02:29 PM EDT
NEUP logo

NEUP Neuphoria Therapeutics Inc.

$3.89
$0.0604
(1.53%)
Today
Mkt Cap$21.35M
Vol32,268.00

About NEUP

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
47

Neutral Sentiment

How do you feel about NEUP?

Advertisement|Remove ads.